Compare Arm Holdings plc (ARM) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Arm Holdings plc vs Neurocrine Biosciences Inc — how do they compare? Arm Holdings plc trades at $315.46 (market cap $345.41B), while Neurocrine Biosciences Inc trades at $175.1 (market cap $17.82B). The key difference: Arm Holdings plc is far larger — about 19.4× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Arm Holdings plc nearer its low. Which is the better fit depends on your goals.
| ARM | NBIX | |
|---|---|---|
Market Cap | $345.41B | $17.82B |
Sector | Technology | Health |
52-Week High | $439.46 | $180.55 |
52-Week Low | $104.55 | $123.10 |
Enterprise Value | $342.26B | $16.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARM Holdings trades at $323.39, down 1.37% over 24 hours, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. The company reported robust revenue growth to $4.01B in 2025, with net income of $792M, though valuation ratios like P/E of 380.46 reflect premium pricing. Recent news highlights ARM's role in AI infrastructure and data center expansion, driving investor optimism.
Outlook remains positive with analyst consensus favoring buy ratings (74.07%) and a $321.65 price target, but risks include high valuation sensitivity and competitive pressures in the semiconductor space. Upside potential hinges on continued AI-driven demand and execution of growth initiatives like the AGI CPU launch.
Neurocrine Biosciences (NBIX) trades at $177.11, down 1.91% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows a bullish technical signal with moving averages supporting upward trends, while RSI levels indicate potential overbought conditions. Recent news highlights strong sales growth from Ingrezza and pipeline advancements, including the Soleno acquisition, reinforcing long-term growth prospects in neuroscience.
Outlook remains positive with a consensus price target of $194, offering ~9.5% upside. Key opportunities include expanding product portfolio and blockbuster drug performance, while risks involve pipeline execution and market volatility. The stock's high valuation multiples require sustained growth to justify current levels, but analyst sentiment is overwhelmingly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arm Holdings plc
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
